MUMBAI, July 7 — Here is a piece of news that might not make headlines at the petrol pump, but which could reshape how we think about one of medicine’s most stubborn problems. Reliance Industries, through its subsidiary Strand Life Sciences, has been granted an Indian patent for an early cancer detection technology. The announcement came in a press release on Tuesday.
The patent is for a method that catches cancer earlier. Strand Life Sciences specialises in genomic diagnostics and research.
Reliance, one of India’s largest conglomerates, provides significant resources for research, development, and potential commercialization.
The mechanism behind the patent
Cancer leaves traces. The patented technology is designed to pick up those traces. Strand’s approach appears to address that balance.
What is intriguing is the timing. Reliance Industries acquired Strand Life Sciences several years ago, part of a broader push into healthcare and life sciences.
The company has been quietly building a portfolio in precision medicine. Precision medicine is the idea that treatments should be tailored to the individual’s genetic makeup, rather than a one-size-fits-all approach. A non-invasive early cancer test fits neatly into that vision.
If you can detect cancer early, you can treat it earlier, and with more targeted therapies.
What this means for the pipeline
The patent strengthens Strand’s position in the field. It is one thing to have a promising technology; it is another to have the legal protection that allows you to develop it without competitors copying your work. For a company backed by Reliance, that protection matters.
The resources available for research, development, and potential commercialisation are substantial. Strand already offers a range of genomic tests, including carrier screening for inherited disorders and cancer predisposition testing.
The new patent adds another layer to that offering. It is not yet a product on the market. Patents cover inventions; turning an invention into a reliable clinical test takes years of validation studies, regulatory approvals, and manufacturing scale-up.
But the patent gives Strand a clear runway.
The bigger picture for Indian diagnostics
India has a high burden of cancer, with many cases diagnosed late. Late diagnosis means poorer outcomes and higher costs. A blood test that could screen for multiple cancers at an early stage would be a game-changer.
It would not replace mammograms or colonoscopies, but it could complement them. The market for such tests is global, and Strand, with Reliance’s backing, is positioned to compete.
Reliance Industries is best known for oil refining, telecommunications, and retail. Its move into healthcare diagnostics might seem like a departure, but it fits a pattern. The company has been diversifying aggressively, and healthcare is a sector with long-term growth potential.
Strand gives Reliance a foothold in genomics, which is widely seen as the next frontier in medicine. What researchers found, and what the patent protects, is a method that could make cancer screening as routine as a cholesterol test.
That is the vision, at least. The reality will depend on how quickly Strand can move from patent to product, and whether the test performs as well in real-world settings as it does in the lab. The press release on Tuesday did not give a timeline for commercial launch.
It did not specify which cancers the test targets. Those details will matter. But for now, the patent is a signal — a marker that one of India’s largest companies is betting on early detection as the next big thing in cancer care.
